Drug Use Investigation for HEPSERA (Adefovir) Tablet

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01863589

Enrollment

436

Registered

2013-05-29

Start date

2005-02-28

Completion date

2012-07-31

Last updated

2013-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis B

Brief summary

This post-marketing surveillance (PMS) is conducted to collect safety and efficacy data among subjects with chronic hepatitis B and hepatic cirrhosis B who is treated with adefovir tablets.

Interventions

DRUGAdefovir tablets

Administered according to the prescribing information in the locally approved label by the authorities.

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Subjects with chronic hepatitis B or hepatic cirrhosis B * Subjects treated with adefovir tablets

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame
The incidence of adverse drug reactions	1 year

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026